Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Parasitic fish could lead to more effective treatments for brain disease
Molecules from sea lampreys could be combined with other therapies to deliver drugs directly to the human brain.

Researchers assess the effectiveness of sea lamprey molecules on glioblastoma

A parasitic fish renowned for its distinctive, disc-shaped mouth could pave the way to more effective treatments for brain conditions, including cancer and stroke.
 
Native to the Northern Hemisphere, the sea lamprey is an ancient species of fish that closely resembles an eel. Its mouth is filled with sharp, hook-shaped teeth, that it uses to feed off other fish.

Now, new research suggests that molecules from sea lampreys could be combined with other therapies to deliver drugs directly to the human brain.

The study, led by the universities of Wisconsin-Madison and Texas, looked at a set of molecules from the lamprey’s immune system called VLRs (variable lymphocyte receptors). While most medicines target specific features on or inside an individual’s cells, VLRs are different because they target the extracellular matrix (ECM) - a mesh of proteins and sugars that both surround and support brain cells.

Researchers believe these molecules could be adapted and combined with an array of other therapies, giving hope to people with brain tumours, multiple sclerosis, Alzheimer’s disease or even traumatic head injuries.

“This set of targeting molecules appears somewhat agnostic to the disease,” says Eric Shusta, a professor of chemical and biological engineering at UW–Madison. “We believe it could be applied as a platform technology across multiple conditions.”

The technology takes advantage that many diseases disrupt the blood-brain barrier. This is what lines the blood vessels of the central nervous system and protects the brain from toxins and pathogens.
In some illnesses, this blood-brain barrier leaks around the disease area, offering a unique entry point for any treatment.

In the study, researchers assessed the effectiveness of VLRs in mouse models of glioblastoma, an incurable brain cancer. The team bound the VLRs to an approved chemotherapy drug called doxorubicin and found that the treatment prolonged the rodents’ survival.

The team note that it’s possible that drugs delivered to the matrix could accumulate to a much higher therapeutic dose than medicines aimed at the inside of cells.

Collaborator John Kuo, a neurosurgeon-scientist and professor of neurosurgery at the University of Texas at Austin, said: “Similar to water soaking into a sponge, the lamprey molecules will potentially accumulate much more of the drug in the abundant matrix around cells compared to specific delivery to cells.”

The team are now planning to link the VLR molecules to additional anti-cancer drugs, such as immunotherapy agents that activate a patient’s own immune system to destroy tumours. They also see promise in using the molecules as diagnostic tools to detect blood-brain barrier disruption.

“I’m excited about trying this strategy in different disease model systems,” says Kuo. “There are several disease processes that disrupt the blood-brain barrier and we could conceive of delivering a variety of different therapies with these molecules.”

The study, Identification of variable lymphocyte receptors that can target therapeutics to pathologically exposed brain extracellular matrix, is published in the journal Science Advances.

Image (C) NOAA Great Lakes Environmental

Become a member or log in to add this story to your CPD history

Charities' XL bully neutering scheme closes

News Story 1
 A scheme that helped owners of XL bully dogs with the cost of neutering has closed to new applications due to high demand.

The scheme, run by the RSPCA, Blue Cross, and Battersea, has helped 1,800 dogs and their owners after XL bullies were banned under the Dangerous Dogs Act.

In England and Wales, owners of XL bully dogs which were over one year old on 31 January 2021 have until 30 June 2024 to get their dog neutered. If a dog was between seven months and 12 months old, it must be neutered by 31 December 2024. If it was under seven months old, owners have until 30 June 2025.

More information can be found on the Defra website. 

Click here for more...
News Shorts
Avian flu cattle outbreak spreads to tenth US state

Cattle in two dairy herds in Iowa have tested positive for highly pathogenic avian influenza (HPAI), making it the tenth state in the USA to be affected by the ongoing outbreak of the disease in cattle.

Since March 2024, more than 80 herds across the USA have been affected by the virus and three dairy workers have tested positive. Authorities have introduced measures to limit the spread of the virus and farmers have been urged to strengthen their biosecurity protocols.

Mike Naig, Iowa secretary of agriculture, said: "Given the spread of highly pathogenic avian influenza within dairy cattle in many other states, it is not a surprise that we would have a case given the size of our dairy industry in Iowa.

"While lactating dairy cattle appear to recover with supportive care, we know this destructive virus continues to be deadly for poultry."